Login to Your Account

PDAC Weighs Risks, Benefits of Implantable Buprenorphine

By Catherine Shaffer
Staff Writer

Friday, March 22, 2013
Safety concerns were front and center at Thursday's meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) reviewing Titan Pharmaceuticals Inc.'s application for Probuphine, an implantable device delivering a steady dose of buprenorphine for up to six months for opioid dependence.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription